PulmOne

Desktop Device for Pulmonary Function Testing

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in March 2006 by Avi Lazar, PulmOne operates with 51–200 employees. The company has raised $13.71M across 5 funding rounds from 2 investors. In December 2021, PulmOne received funding from Alpha LTI and OurCrowd.

Business overview

PulmOne is a Health Tech & Life Sciences company focused on developing patient-friendly, accurate, and cost-effective devices for pulmonary function testing. Its core product, the MiniBox, is a desktop system designed for measuring lung volume and spirometry without relying on a plethysmograph or external gas source. The MiniBox+ extends this capability by adding a diffusing capacity (DLCO) module, offering a complete solution for diagnosing, treating, and monitoring respiratory diseases. PulmOne serves healthcare providers, hospitals, and clinics in the medical devices and diagnostics sectors, with a presence in geomarkets including Europe, the United States, and Japan.

Strategic signal

In November 2019, PulmOne expanded its product offering by integrating FeNO by NIOX® with its MiniBox+™ Complete Pulmonary Function Testing System. This strategic move enhances the diagnostic capabilities of PulmOne's devices, providing a more comprehensive solution for respiratory disease assessment. For investors, this signals the company's commitment to continuous product development and market expansion through partnerships, aiming to capture a larger share of the pulmonary diagnostics market.

Log in to access full profile

Company Intelligence Q&A

What is PulmOne's primary product?
PulmOne's primary product is the MiniBox, a desktop device for measuring lung volume and spirometry. The MiniBox+ offers an enhanced version with a diffusing capacity (DLCO) module for a complete pulmonary function testing solution.
When was PulmOne founded and by whom?
PulmOne was founded in March 2006 by Avi Lazar.
What significant product enhancement did PulmOne announce in late 2019?
In November 2019, PulmOne announced that it was offering FeNO by NIOX® with its MiniBox+™ Complete Pulmonary Function Testing System, expanding its diagnostic capabilities.
Which investors participated in PulmOne's December 2021 funding round?
This round was a Convertible Debt funding type.
What regulatory clearances has PulmOne received for its products?
PulmOne has received FDA 510k clearance and a CE mark for its first product, enabling sales in several locations.
Log in to access full profile